Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Atorvastatin
Atorvastatin pediatric appropriate formulation · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Reference | OTHER | Commercial 80 mg atorvastatin tablet |
| Test | OTHER | Pediatric appropriate atorvastatin 40mg formulation |
| Name | Type | Description |
|---|---|---|
| Atorvastatin | DRUG | A single dose of 80 mg atrovastatin tablet |
| Atorvastatin pediatric appropriate formulation | DRUG | A single dose of pediatric appropriate atorvastatin 80 mg formulation |
Inclusion Criteria: * Healthy male and/or female volunteers * Mass Index (BMI) of approximately 18 to 30 kg/m2 Exclusion Criteria: * Any condition possibly affecting drug absorption * A positive urine drug screening
Top 12 of 15 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 4 | PHASE3 | Enlicitide |
| Novartis AG Sponsored ADR | NVS | 14 | PHASE3 | Inclisiran, Pelacarsen, DII235, QCZ484 |
| AstraZeneca PLC | AZN | 3 | PHASE3 | AZD0780, Laroprovstat, Rosuvastatin |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 5 | PHASE3 | Plozasiran, zodasiran, VSA003 |
| Ionis Pharmaceuticals, Inc. | IONS | 2 | PHASE3 | Olezarsen, ION775 |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE2 | Alirocumab |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Solbinsiran |
| MediciNova, Inc. | MNOV | 1 | PHASE2 | MN-001 |
| Verve Therapeutics, Inc. | VERV | 4 | PHASE2 | VERVE-102, VERVE-201 |
| NewAmsterdam Pharma Company N.V. | NAMS | 1 | PHASE1 | Obicetrapib |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX310 |
| Esperion Therapeutics, Inc. | ESPR | 1 | - | Bempedoic acid+ Ezetimibe |
Atorvastatin pediatric appropriate formulation is an investigational small molecule developed by Pfizer, Inc. (ticker PFE) for hypercholesterolemia. It is a pediatric-oriented version of atorvastatin studied in a Phase 1 bioequivalence trial. The program is in clinical development and is not described as approved.
Atorvastatin pediatric appropriate formulation targets HMGCR, also known as HMG-CoA reductase. It acts as an inhibitor of this enzyme, the same molecular target class as other statin therapies used to lower cholesterol. The drug is a small molecule being studied in hypercholesterolemia.
Pfizer, Inc. is the developer of Atorvastatin pediatric appropriate formulation. Pfizer trades under the ticker PFE. The company is running the clinical program for this pediatric-oriented atorvastatin formulation in hypercholesterolemia.
Atorvastatin pediatric appropriate formulation is in Phase 1 development. One Phase 1 trial has been completed, and no trials are currently active. The program remains investigational and is not described as FDA approved.
Atorvastatin pediatric appropriate formulation has been studied in one completed Phase 1 trial, NCT00758004, titled Bioequivalence Study Of Pediatric Appropriate Formulation. That randomized, controlled trial enrolled 76 healthy adult volunteers in the United States and evaluated hypercholesterolemia-related bioequivalence. No active trials are ongoing.